At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 44 enrolled
Drug / intervention
PRO 140 (humanized monoclonal antibody to CCR5) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a, Randomized, Double-blind, Placebo Controlled Study of PRO 140 by Subcutaneous Administration in Adult Subjects With Human Immunodeficiency Virus Type 1 Infection
In Brief
A Phase 2 clinical trial evaluating PRO 140 (humanized monoclonal antibody to CCR5) and Placebo Comparator for HIV -1 Infection and HIV Infections. Completed, enrolled 44 participants across 1 site.
Detailed Summary
The purpose of this study is: 1. To assess the antiviral activity of PRO 140 2. To assess the safety and tolerability of PRO 140 3. To generate additional PK, PD and safety data of PRO 140
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV -1 Infection, HIV Infections
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2008
First PostedMar 2008
Primary CompletionNov 2008
TodayJul 2026
First PostedMar 25, 2008
Enrollment StartMar 1, 2008
Primary CompletionNov 1, 2008
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 18.3 years ago
Interventions
PRO 140 (humanized monoclonal antibody to CCR5)drug
Placebo Comparatordrug